Decoding Recurrence in Early-Stage and Locoregionally Advanced Non–Small Cell Lung Cancer: Insights From Electronic Health Records and Natural Language Processing

Le résumé fourni par la source

PURPOSE Recurrences after curative resection in early-stage and locoregionally advanced non–small cell lung cancer (NSCLC) are common, necessitating a nuanced understanding of associated risk factors. This study aimed to establish a natural language processing (NLP) system to efficiently curate recurrence data in NSCLC and analyze risk factors longitudinally. PATIENTS AND METHODS Electronic health records of 6,351 patients with NSCLC with >700,000 notes were obtained from Mount Sinai's data sets. A deep learning–based customized NLP system was developed to identify cohorts experiencing recurrence. Recurrence types and rates over time were stratified by various clinical features. Cohort description analysis, Kaplan-Meier analysis for overall recurrence-free survival (RFS) and distant metastasis-free survival (DMFS), and Cox proportional hazards analysis were performed. RESULTS Of 1,295 patients with stage I–IIIA NSCLC with surgical resections, 336 patients (25.9%) experienced recurrence, as identified through NLP. The NLP system achieved a precision of 94.3%, a recall of 93%, and an F1 score of 93.5. Among 336 patients, 52.4% had local/regional recurrences, 44% distant metastases, and 3.6% unknown recurrence. RFS rates at years 1-5 were 93%, 81%, 73%, 67%, and 61%, respectively (96%, 89%, 84%, 80%, and 75% for distant metastasis). Stage-specific RFS rates at year 5 were 73% (IA), 62% (IB), 47% (IIA), 46% (IIB), and 20% (IIIA). Stage IB patients had a significantly higher likelihood of recurrence versus stage IA (adjusted hazard ratio [aHR], 1.63; P = .02). The RFS was lower in patients with clinically significant TP53 alteration ( v TP53 -negative or unknown significance), affecting overall RFS (aHR, 1.89; P = .007) and DMFS (aHR, 2.47; P = .009) among stage IA/IB patients. CONCLUSION Our scalable NLP system enabled us to generate real-world insights into NSCLC recurrences, paving the way for predictive models for preventing, diagnosing, and treating NSCLC recurrence.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.